For those with moderate-to-severe eczema, it can be incredibly discouraging finding a medication that works properly. The ADVISE Study is evaluating the effectiveness of an investigational medication, which would be taken orally, on those with moderate-to-severe eczema.
This study will last up to 20 weeks (4 week screening period, 12 week treatment, 4 week follow-up = 20 weeks) with each participant getting either a 1mg, 2mg dose of the study medication, or a placebo. The participants will take the drug once daily.
It’s important for studies, like the ADVISE Study, to continue to research everything associated with this uncomfortable condition. There is still so much to learn about moderate-to-severe eczema and with each piece of information gathered, we get closer to finding a more effective way to treat it.